Provided by Tiger Trade Technology Pte. Ltd.

PepGen Inc.

4.67
+0.19004.24%
Post-market: 4.670.00000.00%17:19 EST
Volume:1.02M
Turnover:4.62M
Market Cap:321.05M
PE:-1.65
High:4.72
Open:4.50
Low:4.25
Close:4.48
52wk High:7.80
52wk Low:0.8801
Shares:68.75M
Float Shares:45.78M
Volume Ratio:1.40
T/O Rate:2.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8262
EPS(LYR):-2.8490
ROE:-62.25%
ROA:-34.09%
PB:1.97
PE(LYR):-1.64

Loading ...

Desert Control AS Appoints David Borah as Chief Financial Officer

Reuters
·
Feb 03

PepGen Inc. Files Initial Statement of Beneficial Ownership for Chief Business & Legal Officer Joseph Vittiglio

Reuters
·
Dec 11, 2025

PepGen Grants Stock Options to New Chief Business and Legal Officer

Reuters
·
Dec 09, 2025

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) to Newly Appointed Chief Business and Legal Officer

THOMSON REUTERS
·
Dec 09, 2025

BRIEF-PepGen Appoints Joseph Vittiglio, Esq., As Chief Business And Legal Officer

Reuters
·
Dec 08, 2025

PepGen Names Joseph Vittiglio Chief Business and Legal Officer

Reuters
·
Dec 08, 2025

PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer

THOMSON REUTERS
·
Dec 08, 2025

PepGen Inc. (PEPG) Gets a Sell from Bank of America Securities

TIPRANKS
·
Nov 16, 2025

Wedbush Raises Price Target on PepGen to $9 From $8, Keeps Outperform Rating

MT Newswires Live
·
Nov 13, 2025

PepGen price target raised to $20 from $18 at H.C. Wainwright

TIPRANKS
·
Nov 13, 2025

PepGen Inc. Strengthens Financial Position Amid Ongoing Losses

TIPRANKS
·
Nov 13, 2025

PepGen Receives US Patent for Investigational Candidate for Severe Neuromuscular Disease Treatment

MT Newswires Live
·
Nov 12, 2025

PepGen announces issuance of patent for PGN-EDODM1

TIPRANKS
·
Nov 12, 2025

PepGen Inc - Patent Provides Exclusivity for Pgn-Edodm1 in U.S. Until 2042

THOMSON REUTERS
·
Nov 12, 2025

PepGen Q3 EPS $(0.52) Beats $(0.59) Estimate

Benzinga
·
Nov 12, 2025

Biotech firm PepGen's Q3 net loss narrows to $18 mln

Reuters
·
Nov 12, 2025

PepGen Inc. Granted U.S. Patent for Proprietary PGN-EDODM1 Molecule, Extending Exclusivity Into 2042

Reuters
·
Nov 12, 2025

BRIEF-PepGen Q3 EPS USD -0.52

Reuters
·
Nov 12, 2025

PepGen reports third quarter net loss of $18.0 million

Reuters
·
Nov 12, 2025

PepGen Q3 Operating Expenses USD 18.654 Million

THOMSON REUTERS
·
Nov 12, 2025